ICON Public (NASDAQ:ICLR) Given New $290.00 Price Target at Citigroup

ICON Public (NASDAQ:ICLR) had its price target cut by Citigroup from $300.00 to $290.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other research analysts also recently issued reports on ICLR. Robert W. Baird cut their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. The Goldman Sachs Group reduced their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Leerink Partners reissued an “outperform” rating and set a $255.00 price objective (down from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Evercore ISI reduced their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Baird R W cut ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $287.00.

ICON Public Stock Down 1.5 %

Shares of NASDAQ ICLR opened at $219.34 on Monday. The stock has a market capitalization of $18.09 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20. ICON Public has a 52 week low of $183.38 and a 52 week high of $347.72. The firm has a 50-day moving average price of $211.42 and a 200 day moving average price of $273.13. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same period last year, the firm earned $3.10 EPS. ICON Public’s revenue was down 1.2% compared to the same quarter last year. Equities research analysts anticipate that ICON Public will post 13.42 EPS for the current fiscal year.

Hedge Funds Weigh In On ICON Public

Large investors have recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC purchased a new stake in shares of ICON Public during the 2nd quarter valued at $54,000. GAMMA Investing LLC grew its position in ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the period. EverSource Wealth Advisors LLC increased its stake in ICON Public by 39.2% during the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after acquiring an additional 111 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares during the period. Finally, First Horizon Advisors Inc. lifted its stake in shares of ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.